


Progress is being made in treating sarcomas in adolescents and young people
Despite age-specific difficulties, increased understanding of sarcoma biology is leading the way to the development of new treatment strategies

Do the pros of neoadjuvant chemotherapy in sarcoma outweigh the cons?
Neoadjuvant chemotherapy is on course to become standard treatment for selected high-risk soft tissue sarcomas but effects in low-risk disease are unclear

Incorporating proteomics into sarcoma research: where do we stand?
Proteomic research on sarcomas is only in its infancy, but it offers potential in terms of improved biological understanding, identification of new treatment targets and generating biomarkers for patient selection and prognosis prediction

What is on the horizon for the management of osteosarcoma?
2021 ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guidelines open the door to genetic testing but the search for new treatments continues

Single-agent doxorubicin – is it still the standard first-line therapy for all soft tissue sarcoma subtypes?
In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard